Breaking: H.C. Wainwright Reiterates $6.0 Target Price On Eyegate (EYEG) Shares, Reiterates Their Original Buy Rating

February 16, 2018 - By Winifred Garcia

 Breaking: H.C. Wainwright Reiterates $6.0 Target Price On Eyegate (EYEG) Shares, Reiterates Their Original Buy Rating

Eyegate (EYEG) Rating Reaffirmed

H.C. Wainwright now has a $6.0 price target on shares of Eyegate (EYEG). The price target indicates a potential upside of 837.50 % from the close price of Eyegate (EYEG). This rating was disclosed in a research note on Thursday morning.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Coverage

Among 2 analysts covering Eyegate Pharma… (EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharma… has $600 highest and $3.0 lowest target. $3’s average target is 368.75% above currents $0.64 stock price. Eyegate Pharma… had 8 analyst reports since April 7, 2016 according to SRatingsIntel. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) earned “Buy” rating by H.C. Wainwright on Thursday, November 9. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 2. As per Tuesday, August 8, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) on Wednesday, June 14 with “Buy” rating. The company was maintained on Wednesday, November 15 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, February 6 by H.C. Wainwright. On Thursday, April 7 the stock rating was initiated by Noble Financial with “Buy”. The rating was maintained by H.C. Wainwright on Tuesday, December 19 with “Buy”.

The stock increased 6.67% or $0.04 during the last trading session, reaching $0.64. About 33,459 shares traded. Eyegate Pharmaceuticals, Inc. (EYEG) has declined 40.33% since February 16, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

Analysts await Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report earnings on February, 22. They expect $-0.26 earnings per share, up 31.58 % or $0.12 from last year’s $-0.38 per share. After $-0.24 actual earnings per share reported by Eyegate Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $11.01 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More notable recent Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: which released: “EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract …” on February 05, 2018, also with their article: “EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for …” published on August 01, 2017, published: “Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of …” on December 19, 2017. More interesting news about Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were released by: and their article: “Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position” published on January 04, 2018 as well as‘s news article titled: “Eyegate Pharma stock surges 11% after receiving Valeant milestone payment” with publication date: May 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: